written on 01.04.2014

Bayer targets €500m after EU OK for Adempas


This is the first drug to be approved in the EU for chronic thromboembolic pulmonary hypertension (CTEPH), a rare disease estimated to affect around 8-40 people per million globally. The patient population is similar to Adempas's other newly approved…

Latest Reports